Opinion statement
Proper diagnosis of dementia with Lewy bodies (DLB) in clinical practice remains suboptimal as many cases are misdiagnosed, usually as Alzheimer disease (AD) or Parkinson’s disease (PD) and, in rare cases, psychosis. Therefore, it is important for patients with dementia to be thoroughly evaluated by a specialist who is familiar with current diagnostic tests and treatment options. New diagnostic criteria from the Dementia with Lewy Bodies Consortium have been developed to increase diagnostic sensitivity for DLB (Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium; McKeith et al.; Neurology, 89(1): 88–100). REM sleep behavior disorder (RBD) has been studied more thoroughly in correlation with DLB and is now considered a core feature. D2 receptor blocking antipsychotics, which can cause severe antipsychotic sensitivity, are now rarely prescribed for treatment. Therefore, severe antipsychotic sensitivity, which was a suggestive criterion for DLB diagnosis, is now listed as a supportive feature. Reduced DAT uptake in basal ganglia demonstrated by SPECT or PET imaging has high specificity (90%) for distinguishing DLB from AD. Reduced uptake on metaiodobenzylguanidine myocardial scintigraphy correlates with reduced postganglionic sympathetic cardiac innervation in Lewy body diseases, which can increase specificity for discriminating probable DLB from probable AD in milder cases of dementia. However, the latter is more commonly used in Japan and is not used in the USA. The evidence supporting the benefit of other therapeutic modalities is limited in DLB due to lack of extensive studies. There are no FDA-approved medications for the treatment of DLB, although some effective drugs have been used off label to treat various symptoms.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Kosaka K, Matsushita M, Oyanagi S, Mehraein P. A cliniconeurophathological study of the “Lewy body disease”. Seishin Shinkeigaku Zasshi. 1980;82(5):292–311.
Tousi B, Flanigan P, Khosravi M. Impaired Color Vision in Patients with DLB or Prodromal DLB. [abstract]. Mov Disord. 2017;32(2). http://www.mdsabstracts.org/abstract/impaired-color-vision-in-patients-with-dlbor-prodromal-dlb/. Accessed September 20, 2017.
Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012;27(7):913–6.
Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol. 2011;69(5):811–8.
•• McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. This guideline provides an up to date diagnostic criteria for dementia with Lewy bodies.
Manabe Y, Inui Y, Toyama H, Kosaka K. 123I-Metaiodobenzylguanidine myocardial scintigraphy with early images alone is useful for the differential diagnosis of dementia with Lewy bodies. Psychiatry Res. 2017;261:75–9.
Park KW, Kim HS, Cheon SM, Cha JK, Kim SH, Kim JW. Dementia with Lewy bodies versus Alzheimer’s disease and Parkinson’s disease dementia: a comparison of cognitive profiles. J Clin Neurol. 2011;7(1):19–24.
Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord. 2004;19(1):60–7.
Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;70(2):157–64.
Yamamoto E, Mourany L, Colleran R, Whitman C, Tousi B. Utility of Montreal Cognitive Assessment in differentiating dementia with Lewy bodies from Alzheimer’s dementia. Am J Alzheimers Dis Other Demen. 2017;1:1533317517725811.
Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1215–20.
Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683–97.
McKeith I. Top cited papers in international psychogeriatrics: 1. Long-term use of rivastigmine in patients with dementia with lewy bodies: an open-label trial. Int Psychogeriatr. 2009;21(1):5. discussion 5-6
• Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4. This manuscript provides information regarding the first large randomized clinical trial of donepezil in dementia with Lewy bodies.
Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of phase III trial. Alzheimers Res Ther. 2015;7(1):5.
Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.
Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.
Donepezil. http://www.pdr.net. Updated 2017. Accessed Sept 2017.
Rivastigmine. http://www.pdr.net. Updated 2017. Accessed Sept 2017.
Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;127:45–63.
Levodopa. http://www.pdr.net. Accessed Sept 2017.
MHRA. Citalopram 40mg/ml oral drops, solution. www.mhra.gov.uk/home/groups/par/documents/websiteresources/con049076.pdf. Updated 2017. Accessed Sept 2017.
Kosaka K. Diffuse Lewy body disease in Japan. J Neurol. 1990;237(3):197–204.
Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer’s disease. Clinical and pathological findings. Br J Psychiatry. 1993;162:385–92.
Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology. 1990;40(1):1–8.
McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with lewy bodies (DLB): report of the consortium on DLB international workshop. J Alzheimers Dis. 2006;9(3 Suppl):417–23.
Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002;59(1):102–12.
Luis CA, Mittenberg W, Gass CS, Duara R. Diffuse Lewy body disease: clinical, pathological, and neuropsychological review. Neuropsychol Rev. 1999;9(3):137–50.
Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46(1):101–6.
Boot BP, Orr CF, Ahlskog JE, et al. Risk factors for dementia with lewy bodies: a case-control study. Neurology. 2013;81(9):833–40.
Breitve MH, Hynninen MJ, Bronnick K, et al. A longitudinal study of anxiety and cognitive decline in dementia with lewy bodies and Alzheimer’s disease. Alzheimers Res Ther. 2016;8:3.
Tousi B, Mourany L. Correlation between neuro-behavioral symptoms, cognition and gait in patients with dementia with Lewy bodies (DLB) [abstract]. Mov Disord. 2016;31(2). http://www.mdsabstracts.org/abstract/correlation-between-neuro-behavioralsymptoms-cognition-and-gait-in-patients-with-dementia-with-lewy-bodies-dlb/. Accessed September 20, 2017.
Factora RM, Tousi B. Don’t forget non-Alzheimer dementias. Cleve Clin J Med. 2014;81(4):243–54.
Thaipisuttikul P, Lobach I, Zweig Y, Gurnani A, Galvin JE. Capgras syndrome in dementia with Lewy bodies. Int Psychogeriatr. 2013;25(5):843–9.
Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with lewy bodies: a case series. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27(3):549–53.
Kurlan R, Cummings J, Raman R, Thal L. Alzheimer’s disease cooperative study group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–63.
Quetiapine. http://www.pdr.net. Updated 2017. Accessed Sept 2017.
Clozapine. http://www.pdr.net. Updated 2017. Accessed Sept 2017.
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40. This article provides the results of the pivotal study for pimavanserine as first FDA-approved treatment for neuropsychiatric symptom of a neurodegenerative disease.
Friedman JH. A retrospective study of pimavanserin use in a movement disorders clinic. Clin Neuropharmacol. 2017;40:157–9.
Chwiszczuk L, Breitve M, Hynninen M, Gjerstad MD, Aarsland D, Rongve A. Higher frequency and complexity of sleep disturbances in dementia with lewy bodies as compared to Alzheimer’s disease. Neurodegener Dis. 2016;16(3–4):152–60.
Elder GJ, Colloby SJ, Lett DJ, et al. Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies. Int J Geriatr Psychiatry. 2016;31(7):765–70.
Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435–63.
Prado E, Paholpak P, Ngo M, et al. Agitation and psychosis associated with dementia with Lewy bodies exacerbated by modafinil use. Am J Alzheimers Dis Other Demen. 2012;27(7):468–73.
Lapid MI, Kuntz KM, Mason SS, et al. Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies: a pilot study. Dement Geriatr Cogn Disord. 2017;43(5–6):269–80.
Kazui H, Adachi H, Kanemoto H, et al. Effects of donepezil on sleep disturbances in patients with dementia with Lewy bodies: an open-label study with actigraphy. Psychiatry Res. 2017;251:312–8.
McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19–26.
St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson’s disease and other synucleinopathies. Mov Disord. 2017;32(5):645–58.
Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.
Clonazepam. http://www.pdr.net. Updated 2017. Accessed Sept 2017.
Schenck CH, Milner DM, Hurwitz TD, Bundlie SR, Mahowald MW. A polysomnographic and clinical report on sleep-related injury in 100 adult patients. Am J Psychiatry. 1989;146(9):1166–73.
Kasanuki K, Iseki E, Nishida Y, et al. Effectiveness of ramelteon for treatment of visual hallucinations in dementia with lewy bodies: a report of 4 cases. J Clin Psychopharmacol. 2013;33(4):581–3.
Ramelteon. http://www.pdr.net. Accessed Sept 2017.
Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer’s disease, dementia with lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690–705.
Al-Shamma HA, Anderson C, Chuang E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther. 2010;332(1):281–90.
Wen W, Friedhoff L, Kishnani K, Ramaswamy S, Piscitelli S, Sanchez M, Shanahan W. Safety of nelotanserin in a randomized placebo-controlled phase 2 study [abstract]. Mov Disord. 2016;31(2). http://www.mdsabstracts.org/abstract/safety-of-nelotanserin-in-a-randomizedplacebo-controlled-phase-2-study. Accessed September 20, 2017.
Lombardo I, Ramaswamy G, Piscitelli S, Friedhoff L. The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: completer analysis of a phase 2b study. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. 2015;11(7):332.
Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564–6.
Acknowledgements
The author thanks Amy Slugg Moore, BA, for her critical reading of the manuscript and editorial support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Babak Tousi has received grants and personal fees from Axovant and Grifols, personal fees from Lilly, and grants from the Alzheimer’s Drug Discovery Foundation and Neuronix.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Dementia
Rights and permissions
About this article
Cite this article
Tousi, B. Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies. Curr Treat Options Neurol 19, 42 (2017). https://doi.org/10.1007/s11940-017-0478-x
Published:
DOI: https://doi.org/10.1007/s11940-017-0478-x